Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced that Caris, the Caris Precision Oncology Alliance® (Caris POA) and collaborators from more than 60 institutions will collectively present 32 studies at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, including one rapid oral presentation and multiple posters across 10 tumor types as well as pan-cancer analyses. These studies reflect the use of multi-omic biomarker research and real-world data to advance understanding of tumor biology and help inform precision oncology approaches.
Highlighted research being presented at the 2026 ASCO Annual Meeting includes breast, colorectal, lung, endometrial and renal cell carcinoma studies, in addition to pan-cancer analyses. These studies are retrospective, real-world analyses and multi-omic biomarker investigations focused on immuno-oncology, tumor microenvironment characterization, and predicting treatment response and resistance.
“Caris is proud to collaborate with leading academic and clinical institutions to advance large-scale, multi-omic research and real-world evidence generation,” said Caris EVP and Chief Medical Officer George W. Sledge, Jr., MD. “The breadth of research being presented at ASCO reflects the importance of comprehensive molecular profiling and data-driven discovery to support continued progress in precision oncology.”
Among the data to be presented are two Caris-led studies evaluating novel biomarker insights. One study examines how genetic ancestry influences ultraviolet (UV)-related mutational signatures in melanoma and their association with immunotherapy response. A second study evaluates ESR1 amplification in breast cancer, identifying it as a distinct genomic subtype associated with reduced survival and decreased benefit from CDK4/6 inhibitor therapies.
The 32 studies represent collaborations with cancer centers, academic institutions and research organizations across the United States, Europe, Asia and the Middle East, including Dana-Farber Cancer Institute, Mayo Clinic, Memorial Sloan Kettering Cancer Center and the National Cancer Institute.
